Rosuvastatin + Atorvastatin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Feb 1, 2006 → Jun 1, 2009

NCT ID

NCT00296400

About Rosuvastatin + Atorvastatin

Rosuvastatin + Atorvastatin is a phase 2 stage product being developed by AstraZeneca for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00296400. Target conditions include Hyperlipidemia.

What happened to similar drugs?

6 of 20 similar drugs in Hyperlipidemia were approved

Approved (6) Terminated (1) Active (13)

🔄YHP1701 + YHR1703 + YHR1704YuhanPhase 3

🔄YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3

✅Diet+pravastatinDaiichi SankyoApproved

✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

✅Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved

🔄Pravafen + Pravastatin + FenofibrateShionogiPhase 3

❌Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00683618	Phase 3	Completed	May 1, 2008	Jul 1, 2009	Hypercholesterolemia
NCT00620542	Phase 3	Completed	Jan 1, 2008	Jun 1, 2011	Coronary Atherosclerosis
NCT00427960	Approved	Terminated	Dec 1, 2006	Feb 1, 2008	Hypercholesterolaemia
NCT00395486	Approved	Completed	Sep 1, 2006	Jun 1, 2008	Metabolic Syndrome X
NCT00296400	Phase 2	Completed	Feb 1, 2006	Jun 1, 2009	Hyperlipidemia
NCT00296387	Phase 3	Completed	Jan 1, 2006	Oct 1, 2007	Acute Coronary Syndrome
NCT00329173	Phase 3	Completed	Nov 1, 2003	Aug 1, 2004	Hypercholesterolaemia
NCT00239330	Phase 3	Completed	Jun 1, 2003	Feb 1, 2005	Hypercholesteremia
NCT00653965	Phase 3	Completed	May 1, 2003	Feb 1, 2005	Hypercholesterolemia
NCT00653588	Phase 3	Completed	Apr 1, 2003	Sep 1, 2004	Hypercholesterolemia
NCT00654225	Phase 3	Completed	Oct 1, 2002	Mar 1, 2005	Hypercholesterolemia
NCT00654485	Phase 3	Completed	May 1, 2002	Feb 1, 2005	Metabolic Syndrome
NCT00653744	Phase 3	Completed	Mar 1, 2002	Mar 1, 2004	Hypercholesterolemia

Competing Products

20 competing products in Hyperlipidemia

See all competitors

Product	Company	Stage	Hype Score
DRL-17822 or placebo	Dr. Reddy's Laboratories	Phase 2	32
VK2809 + Placebo	Viking Therapeutics	Phase 2	32
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	40
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo	Yuhan	Phase 3	40
Diet+pravastatin	Daiichi Sankyo	Approved	43
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	43
Minute Maid Heart Wise orange juice + Welchol	Daiichi Sankyo	Approved	43
Pravafen + Pravastatin + Fenofibrate	Shionogi	Phase 3	40
Evacetrapib + Atorvastatin + Ezetimibe + Placebo	Eli Lilly	Phase 3	32
exenatide	Eli Lilly	Pre-clinical	26
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC	Eli Lilly	Phase 1	29
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1209	Jiangsu Hengrui Medicine	Phase 1	29
SHR-1209 + Placebo	Jiangsu Hengrui Medicine	Phase 1/2	32
Rosuvastatin (Crestor)	AstraZeneca	Approved	39
simvastatin + Ezetimibe	Merck	Approved	43
MK-0524A + Atorvastatin + Simvastatin	Merck	Phase 3	40
simvastatin 20 mg/ezetimibe	Merck	Phase 2/3	38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin	Merck	Phase 3	47
Sitagliptin + Placebo	Merck	Phase 2/3	38